We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
-2.31%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$309M
AUM Growth
+$5.25M
Cap. Flow
+$5.62M
Cap. Flow %
1.82%
Top 10 Hldgs %
59.65%
Holding
61
New
4
Increased
8
Reduced
7
Closed
17

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$15.2M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.5M
3
RLAY icon
Relay Therapeutics
RLAY
+$13.7M
4
SWTX
SpringWorks Therapeutics
SWTX
+$8.25M
5
APLS
Apellis Pharmaceuticals
APLS
+$3.65M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$16.9M
2
ARGX icon
argenx
ARGX
+$10.2M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.98M
4
ASTL icon
Algoma Steel
ASTL
+$3.26M
5
FOLD
Amicus Therapeutics
FOLD
+$2.93M

Sector Composition

Rank Sector Weight
1 Healthcare 89.87%
2 Materials 6.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
1
Travere Therapeutics
TVTX
$5.27B
$21.6M 6.98%
1,026,300
-2,575
-0.3% -$54.6K
ASTL icon
2
Algoma Steel
ASTL
$404M
$20.4M 6.6%
3,219,441
-497,291
-13% -$3.26M
PRTA icon
3
Prothena Corp
PRTA
$453M
$19.5M 6.29%
322,900
+17,500
+6% +$1.02M
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.38B
$18.7M 6.06%
1,176,830
+65,800
+6% +$1.03M
CYTK icon
5
Cytokinetics
CYTK
$10.9B
$18.5M 5.97%
402,793
+22,000
+6% +$947K
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$17.4M 5.64%
1,428,475
-259,925
-15% -$2.93M
LKFT
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$17.3M 5.6%
390,359
+10,657
+3% +$448K
APLS
8
DELISTED
Apellis Pharmaceuticals
APLS
$17.3M 5.6%
334,890
+68,800
+26% +$3.65M
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.82B
$17M 5.51%
+131,457
New +$15.2M
SWTX
10
DELISTED
SpringWorks Therapeutics
SWTX
$16.7M 5.41%
643,000
+334,908
+109% +$8.25M
ASND icon
11
Ascendis Pharma A/S
ASND
$17.1B
$16.4M 5.29%
134,036
+10,636
+9% +$1.23M
CERE
12
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$16.3M 5.27%
517,287
-19,614
-4% -$553K
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$15.2M 4.9%
707,600
-280,000
-28% -$5.98M
CRNX icon
14
Crinetics Pharmaceuticals
CRNX
$8.88B
$15.1M 4.87%
+822,745
New +$14.5M
ARVN icon
15
Arvinas
ARVN
$517M
$14.7M 4.75%
429,600
+30,600
+8% +$1.29M
SAGE
16
DELISTED
Sage Therapeutics
SAGE
$14.6M 4.71%
381,765
-47,548
-11% -$1.82M
RLAY icon
17
Relay Therapeutics
RLAY
$4.34B
$10.7M 3.45%
+714,848
New +$13.7M
IOVA icon
18
Iovance Biotherapeutics
IOVA
$2.23B
$9.88M 3.19%
1,545,589
-40,454
-3% -$316K
SLDB icon
19
Solid Biosciences
SLDB
$858M
$1.18M 0.38%
+218,562
New +$1.43M
AAC.WS
20
DELISTED
Ares Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
AAC.WS
$235K 0.08%
504,706
– –
SMIHW
21
DELISTED
Summit Healthcare Acquisition Corp. Warrant
SMIHW
$139K 0.04%
489,999
– –
CORS.WS
22
DELISTED
Corsair Partnering Corporation Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
CORS.WS
$110K 0.04%
334,666
– –
BTWNW
23
DELISTED
Bridgetown Holdings Limited Warrants
BTWNW
$103K 0.03%
895,000
– –
CPAAW
24
DELISTED
Conyers Park III Acquisition Corp. Warrants
CPAAW
$85K 0.03%
571,666
– –
ZTAQW
25
DELISTED
Zimmer Energy Transition Acquisition Corp. Warrants
ZTAQW
$68K 0.02%
358,270
– –
1
2 3

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Finepoint Capital held 61 positions worth $309M, up 1.7% from $304M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Finepoint Capital's Q4 2022 filing shows 4 new, 8 increased, 7 reduced and 17 closed positions. Its largest new stake was Sarepta Therapeutics: 131,457 shares worth $17M. The largest sale was Arcus Biosciences, an estimated $16.9M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Materials.

  • Finepoint Capital's largest Q4 2022 buy was Sarepta Therapeutics: 131,457 shares worth $17M.
  • Finepoint Capital added most to SpringWorks Therapeutics in Q4 2022, an estimated $8.25M increase.
  • Finepoint Capital's biggest Q4 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $5.98M.
  • Finepoint Capital fully exited Arcus Biosciences in Q4 2022, selling an estimated $16.9M.
  • Finepoint Capital's ten largest holdings make up 60% of its $309M portfolio in Q4 2022.
  • Finepoint Capital opened 4 new positions and closed 17 in Q4 2022.
  • Finepoint Capital's portfolio value rose 1.7% quarter-over-quarter to $309M.

Based on Finepoint Capital's 13F filing for Q4 2022, filed 13 Feb 2023.